Support of respiratory compromise

Inspiration

I have worked as an anesthesiologist for 28 years and have treated ARDS in the ICU. The end result of the CoVID19 is an ARDS picture with a physical barrier that prevents oxygenation not ventilation. Mucous clogs the lung so oxygen cannot get through. Hypoxia, the lack of oxygen to organs causes end organ damage and multisystem organ failure and death. This is symptomatic treatment but if we can prevent people from getting on a ventilator with 100% fatality at this point we can save lives until a vaccine or antiviral is developed

What it does

Stimulates receptors in the periphery and the brain to increase respiration

How I built it

Taking the FDA approved IV respiratory stimulant and convert it to a pill. It has been used in neonates in EU, UK, Japan etc to keep neonates off ventilators

Challenges I ran into

Raising money, regulatory issues, getting people to do something different

Accomplishments that I'm proud of

FDA innovation win for iPill, FDA breakthrough designation for iPill, Patent for iPill

What I learned

Thinking outside of the box, thinking differently than others is a lonely but successful road

What's next for Support of respiratory compromise

Single ascending dose study to find the effective dose

Built With

• already
• fda
• is
• oral
• respiratory
• stimulant
• the